- Moleculin Biotech (NASDAQ:MBRX) announces that it intends to offer and sell shares in an underwritten public offering.
- The company plans to use the net proceeds of the offering to fund its planned clinical trials and preclinical programs among other things.
- As part of this offering, Moleculin intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares.
- The company did not provide further details on the potential offering.
- Oppenheimer & Co. is acting as the sole book-running manager for the proposed offering.